RecruitingPhase 2NCT06563323

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Studying Classic pyoderma gangrenosum

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Oregon Health and Science University
Principal Investigator: Alex G Ortega-Loayza, MD, MCR
Oregon Health and Science University, Department of Dermatology
Intervention: Guselkumab(drug)
Enrollment: 17 enrolled
Eligibility: 18-99 years · All sexes
Timeline: 2025 – 2027

Study locations (2)

Ohio State Dermatology, Columbus, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States

Collaborators

Janssen Scientific Affairs, LLC · Ohio State University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06563323 on ClinicalTrials.gov

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT06624670
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Boehringer Ingelheim

See all trials for Classic pyoderma gangrenosum →

← Back to all trials